11,949 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,949 shares of the biopharmaceutical company's stock, valued at approximately $401,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $63,000. Quarry LP bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $78,000. Vident Advisory LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $212,000. NEOS Investment Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $240,000. Finally, Tema Etfs LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $240,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on XENE shares. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Needham & Company LLC cut their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. Wall Street Zen downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Finally, Royal Bank Of Canada dropped their price objective on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.82.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock traded down $0.09 during midday trading on Friday, reaching $30.46. 222,059 shares of the stock were exchanged, compared to its average volume of 869,414. The company's fifty day moving average is $31.50 and its 200-day moving average is $34.41. The firm has a market cap of $2.34 billion, a PE ratio of -9.45 and a beta of 1.10. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same period in the previous year, the company earned ($0.62) EPS. On average, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.